ATE512966T1 - Pyrazolo-pyrimidin-derivate als mglur2- antagonisten - Google Patents

Pyrazolo-pyrimidin-derivate als mglur2- antagonisten

Info

Publication number: ATE512966T1
Authority: AT; Austria
Prior art keywords: pyrazolo; pyrimidine derivatives; mglur2 antagonists; mglur2; antagonists
Prior art date: 2005-02-11

Application number

AT06706609T

Other languages

English (en)

Inventor

Mcarthur Silvia Gatti

Erwin Goetschi

Juergen Wichmann

Thomas Woltering

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-11

Filing date

2006-02-03

Publication date

2011-07-15

2006-02-03 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2011-07-15 Application granted granted Critical

2011-07-15 Publication of ATE512966T1 publication Critical patent/ATE512966T1/de

Links

101150016175 Grm2 gene Proteins 0.000 title 1
102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT06706609T 2005-02-11 2006-02-03 Pyrazolo-pyrimidin-derivate als mglur2- antagonisten ATE512966T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP05101027		2005-02-11
PCT/EP2006/000940 WO2006084634A1 (en)	2005-02-11	2006-02-03	Pyrazolo-pyrimidine derivatives as mglur2 antagonists

Publications (1)

Publication Number	Publication Date
ATE512966T1 true ATE512966T1 (de)	2011-07-15

Family

ID=36090752

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06706609T ATE512966T1 (de)	2005-02-11	2006-02-03	Pyrazolo-pyrimidin-derivate als mglur2- antagonisten

Country Status (18)

Country	Link
US (1)	US7361659B2 (de)
EP (1)	EP1851225B1 (de)
JP (1)	JP4708438B2 (de)
KR (1)	KR100968291B1 (de)
CN (1)	CN101115755B (de)
AR (1)	AR052568A1 (de)
AT (1)	ATE512966T1 (de)
AU (1)	AU2006212457B2 (de)
BR (1)	BRPI0607927A2 (de)
CA (1)	CA2597608C (de)
ES (1)	ES2365406T3 (de)
IL (1)	IL184712A (de)
MX (1)	MX2007009106A (de)
NO (1)	NO20073876L (de)
RU (1)	RU2402553C2 (de)
TW (1)	TW200716120A (de)
WO (1)	WO2006084634A1 (de)
ZA (1)	ZA200706353B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2085398A1 (de) *	2008-02-01	2009-08-05	Merz Pharma GmbH & Co. KGaA	Pyrazolopyrimidine, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel
WO2009110901A1 (en) *	2008-03-06	2009-09-11	Sanofi-Aventis	Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof as allosteric modulators of mglur
US8207181B2 (en)	2008-03-06	2012-06-26	Sanofi	Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof
US20130137865A1 (en)	2010-08-11	2013-05-30	Taisho Pharmaceutical Co., Ltd.	Heteroaryl-pyrazole derivative
US9447099B2 (en) *	2011-10-04	2016-09-20	Hoffmann-La Roche Inc.	Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
JP6073343B2 (ja)	2011-10-20	2017-02-01	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅＬＬＣ	サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
EP2666775A1 (de)	2012-05-21	2013-11-27	Domain Therapeutics	Substituierte Pyrazolochinazolinone und Pyrrolochinazolinone als allosterische Modulatoren von metabotropen Glutamatrezeptoren der Gruppe II
CN104736140A (zh)	2012-10-23	2015-06-24	霍夫曼-拉罗奇有限公司	用于治疗自闭症的mGlu2/3拮抗剂
JP2017513844A (ja)	2014-04-23	2017-06-01	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	知的障害の処置のためのｍＧｌｕ２／３アンタゴニスト
JOP20150179B1 (ar) *	2014-08-01	2021-08-17	Janssen Pharmaceutica Nv	مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
EP3000814A1 (de)	2014-09-26	2016-03-30	Domain Therapeutics	Substituierte Pyrazolochinazolinone und Pyrrolochinazolinone als allosterische Modulatoren von metabotropen Glutamatrezeptoren der Gruppe II
EP4406616A3 (de)	2014-11-06	2024-11-06	Bial-R&D Investments, S.A.	Substituierte pyrazolo(1,5-a)pyrimidine und ihre verwendung bei der behandlung von medizinischen erkrankungen
US20180185368A1 (en)	2014-11-06	2018-07-05	Lysosomal Therapeutics Inc.	Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
US20170333435A1 (en)	2014-11-06	2017-11-23	Lysosomal Therapeutics Inc.	Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
EP3226915B1 (de)	2014-12-03	2019-02-20	Janssen Pharmaceutica NV	Radioaktiv markierte mglur2-pet-liganden
PL236355B1 (pl) *	2015-04-02	2021-01-11	Celon Pharma Spolka Akcyjna	Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
JP6929285B2 (ja)	2015-12-18	2021-09-01	ヤンセンファーマシューティカエヌ．ベー．	放射性標識ｍＧｌｕＲ２／３ＰＥＴリガンド
RS60981B1 (sr)	2015-12-18	2020-11-30	Janssen Pharmaceutica Nv	Radiooznačeni mglur2/3 pet ligandi
CA3020305A1 (en)	2016-04-06	2017-10-12	Lysosomal Therapeutics Inc.	Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3440081A4 (de)	2016-04-06	2019-09-18	Lysosomal Therapeutics Inc.	Pyrrolo[1,2-a]pyrimidinyl-carboxamid-verbindungen und deren verwendung in der behandlung von medizinischen störungen
AU2017246455B2 (en) *	2016-04-06	2021-09-30	Bial - R&D Investments, S.A.	Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
KR102530515B1 (ko)	2016-05-05	2023-05-09	비알 - 알&디 인베스트먼츠, 에스.에이.	치환된 이미다조[1,2-b]피리다진, 치환된 이미다조[1,5-b]피리다진, 관련 화합물, 및 의학적 장애의 치료에서의 그의 용도
WO2017192931A1 (en)	2016-05-05	2017-11-09	Lysosomal Therapeutics Inc.	SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
EP3566749A4 (de) *	2017-01-09	2020-09-23	Medshine Discovery Inc.	Thiazolderivat und anwendungen davon
WO2019103070A1 (ja)	2017-11-24	2019-05-31	大日本住友製薬株式会社	６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体及びその医薬用途
US11964969B2 (en)	2018-07-06	2024-04-23	Phaeno Therapeutics Co., Ltd	Crystal forms of thiazole compound and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU713673B2 (en)	1996-02-07	1999-12-09	Neurocrine Biosciences Inc.	Pyrazolopyrimidines as crf receptor antagonists
ATE214704T1 (de)	1997-07-18	2002-04-15	Hoffmann La Roche	5h-thiazolo(3,2-a)pyrimidinderivate
AU4203500A (en)	1999-04-06	2000-10-23	Du Pont Pharmaceuticals Company	Pyrazolopyrimidines as crf antagonists
CA2442557C (en) *	2001-04-12	2008-12-23	F. Hoffmann-La Roche Ag	Dihydro-benzo¬b\|¬1,4\|diazepin-2-one derivatives as mglur2 antagonists ii
DE602004012083T2 (de) *	2003-04-15	2009-04-23	Astrazeneca Ab	Neue Verbindungen, die als Verstärker von Glutamatrezeptoren dienen
US7329662B2 (en) *	2003-10-03	2008-02-12	Hoffmann-La Roche Inc.	Pyrazolo-pyridine
BRPI0512330A (pt) *	2004-06-21	2008-02-26	Hoffmann La Roche	derivados de pirazol-pirimidina

2006
- 2006-02-03 BR BRPI0607927-0A patent/BRPI0607927A2/pt not_active IP Right Cessation
- 2006-02-03 EP EP06706609A patent/EP1851225B1/de not_active Expired - Lifetime
- 2006-02-03 JP JP2007554484A patent/JP4708438B2/ja not_active Expired - Fee Related
- 2006-02-03 WO PCT/EP2006/000940 patent/WO2006084634A1/en not_active Ceased
- 2006-02-03 CA CA2597608A patent/CA2597608C/en not_active Expired - Fee Related
- 2006-02-03 ES ES06706609T patent/ES2365406T3/es not_active Expired - Lifetime
- 2006-02-03 MX MX2007009106A patent/MX2007009106A/es active IP Right Grant
- 2006-02-03 RU RU2007128624/04A patent/RU2402553C2/ru not_active IP Right Cessation
- 2006-02-03 AT AT06706609T patent/ATE512966T1/de active
- 2006-02-03 KR KR1020077018345A patent/KR100968291B1/ko not_active Expired - Fee Related
- 2006-02-03 AU AU2006212457A patent/AU2006212457B2/en not_active Ceased
- 2006-02-03 CN CN2006800046579A patent/CN101115755B/zh not_active Expired - Fee Related
- 2006-02-06 US US11/348,105 patent/US7361659B2/en not_active Expired - Fee Related
- 2006-02-06 AR ARP060100412A patent/AR052568A1/es not_active Application Discontinuation
- 2006-02-08 TW TW095104260A patent/TW200716120A/zh unknown
2007
- 2007-07-19 IL IL184712A patent/IL184712A/en not_active IP Right Cessation
- 2007-07-24 NO NO20073876A patent/NO20073876L/no not_active Application Discontinuation
- 2007-07-31 ZA ZA200706353A patent/ZA200706353B/xx unknown

Also Published As

Publication number	Publication date
CN101115755B (zh)	2013-01-16
IL184712A0 (en)	2007-12-03
AU2006212457A1 (en)	2006-08-17
JP2008530042A (ja)	2008-08-07
BRPI0607927A2 (pt)	2009-10-20
NO20073876L (no)	2007-09-10
ES2365406T3 (es)	2011-10-04
MX2007009106A (es)	2007-09-11
TW200716120A (en)	2007-05-01
IL184712A (en)	2013-05-30
RU2007128624A (ru)	2009-03-20
EP1851225B1 (de)	2011-06-15
WO2006084634A1 (en)	2006-08-17
US7361659B2 (en)	2008-04-22
EP1851225A1 (de)	2007-11-07
AR052568A1 (es)	2007-03-21
CA2597608C (en)	2013-12-24
KR100968291B1 (ko)	2010-07-07
US20060183756A1 (en)	2006-08-17
KR20070104592A (ko)	2007-10-26
JP4708438B2 (ja)	2011-06-22
ZA200706353B (en)	2009-09-30
CN101115755A (zh)	2008-01-30
AU2006212457B2 (en)	2011-04-14
CA2597608A1 (en)	2006-08-17
RU2402553C2 (ru)	2010-10-27

Legal Events

Date

Code

Title

Description

2012-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1851225

Country of ref document: EP

Publication	Publication Date	Title
ATE512966T1 (de)	2011-07-15	Pyrazolo-pyrimidin-derivate als mglur2- antagonisten
ATE460417T1 (de)	2010-03-15	Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten
DE602006015607D1 (de)	2010-09-02	Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE531705T1 (de)	2011-11-15	Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren
LT2495016T (lt)	2020-02-10	Bicikliniai heteroarilų junginiai
DK2194043T3 (da)	2014-01-20	Fremgangsmåder
ITMI20050728A1 (it)	2006-10-23	Formulazione innovativa
ATE537149T1 (de)	2011-12-15	Sulfonyl-pyrazolinyl-1-carboxamidinderivate als 5-ht6-antagonisten
ATE479676T1 (de)	2010-09-15	Als antikoagulanzien verwendbare phenylglycinamid-derivate
ATE533744T1 (de)	2011-12-15	N-benzoypyrrolidin-3-ylamine als histamin-3 antagonisten
DE602006010508D1 (de)	2009-12-31	Substituierte triazolderivate als oxytocinantagonisten
ATE421511T1 (de)	2009-02-15	Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE547407T1 (de)	2012-03-15	Alkylthiopyrimidine als crth2-antagonisten
DK1937650T3 (da)	2011-10-03	Heterocykliske forbindelser
DK1973886T3 (da)	2013-03-18	Prokineticin-1-receptor-antagonister
DE112005003586A5 (de)	2008-03-06	Bohrfutter
DK1957492T3 (da)	2011-02-28	Substituerede bicykliske pyrimidonderivater
NL2000241A1 (nl)	2007-03-22	Carboxamidederivaten als muscarine-receptorantagonisten.
EP1907393A4 (de)	2011-10-05	Introvertierte cucurbituril-verbindungen
DE602006003666D1 (de)	2008-12-24	Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten
DE602006015186D1 (de)	2010-08-12	Oxindole als kinaseinhibitoren
ATE488519T1 (de)	2010-12-15	Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
DE502006002822D1 (de)	2009-03-26	Ges
FR2884161B1 (fr)	2008-10-10	Architecture de machine-outil
NO20055676D0 (no)	2005-12-01	X-Rail